Blajchman M A
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Vox Sang. 1998;74 Suppl 2:315-9. doi: 10.1111/j.1423-0410.1998.tb05437.x.
Recognition that allogeneic transfusion associated immunomodulation can increase morbidity in allogeneically transfused individuals has become a major concern for those involved in transfusion medicine. However, whether allogeneic blood transfusions predispose recipients to increased risk for cancer recurrence or to bacterial infections is still unproven. In contrast, data from studies in experimental animal models suggest that allogeneic blood transfusion associated immunomodulation is an immunologically mediated biological effect which is associated primarily with the infusion of allogeneic leukocytes. Moreover, the available experimental animal data suggest that pre-storage leukoreduction, as opposed to post-storage leukodepletion, is effective in ameliorating this tumor growth-enhancing effect of allogeneic blood. While considerable data have accumulated in an attempt to unravel the mechanism of the immunomodulatory effect of allogeneic blood transfusions, the precise mechanism of this effect has not yet been elucidated.
认识到异体输血相关的免疫调节会增加接受异体输血个体的发病率，已成为输血医学领域相关人员的主要关注点。然而，异体输血是否会使受血者患癌症复发或细菌感染的风险增加，仍未得到证实。相比之下，实验动物模型研究的数据表明，异体输血相关的免疫调节是一种免疫介导的生物学效应，主要与输注异体白细胞有关。此外，现有的实验动物数据表明，与储存后白细胞去除相反，储存前白细胞滤除可有效改善异体血的这种促进肿瘤生长的效应。尽管为阐明异体输血免疫调节作用的机制已积累了大量数据，但这种效应的确切机制尚未阐明。
